In fact, results of several studies have shown that AZM treatment of patients with CF and non-CF bronchiectasis for 3–6 months improved lung function and nutritional status, while also reducing C-reactive protein levels, pulmonary exacerbations, and hospitalization rates (7–10), but only one multicenter phase 3 trial study was performed that showed similar results included both pediatric and adult PCD patients (14). The gene discussed is CRP; the disease is primary ciliary dyskinesia.